IPI 940

Drug Profile

IPI 940

Alternative Names: FAAH inhibitor - Infinity; IPI-940

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Infinity Pharmaceuticals
  • Class Non-opioid analgesics
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammatory pain; Neuropathic pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Inflammatory-pain(In volunteers) in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in USA (PO)
  • 31 Dec 2012 IPI 940 is available for licensing as of 31 Dec 2012. http://www.infi.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top